Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Colleoni

Showing results (151-160 of 178) with videos related to

Pageof 18
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFTM M Regan, B A Walley, P A Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Identifying breast cancer patients at high risk for bone metastasesM Colleoni, A O'Neill, A Goldhirsch, et al.
British Journal of Cancer|June 28, 2002
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMFM Colleoni, H J Litman, M Castiglione-Gertsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trialA Gennari, Z Sun, U Hasler-Strub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 18, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)L Malorni, S Tyekucheva, A Gombos, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTOS Di Cosimo, C Campbell, H A Azim, et al.
Breast (Edinburgh, Scotland)|June 22, 2026
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancerL Gianni, S Delaloge, E Ciruelos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Pageof 18

Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFTM M Regan, B A Walley, P A Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Identifying breast cancer patients at high risk for bone metastasesM Colleoni, A O'Neill, A Goldhirsch, et al.
British Journal of Cancer|June 28, 2002
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMFM Colleoni, H J Litman, M Castiglione-Gertsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trialA Gennari, Z Sun, U Hasler-Strub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 18, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)L Malorni, S Tyekucheva, A Gombos, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTOS Di Cosimo, C Campbell, H A Azim, et al.
Breast (Edinburgh, Scotland)|June 22, 2026
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancerL Gianni, S Delaloge, E Ciruelos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Pageof 18